MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
3.750
-0.020
-0.53%
After Hours: 3.790 +0.04 +1.07% 17:52 12/05 EST
OPEN
3.800
PREV CLOSE
3.770
HIGH
3.900
LOW
3.615
VOLUME
70.57K
TURNOVER
--
52 WEEK HIGH
6.12
52 WEEK LOW
2.550
MARKET CAP
41.94M
P/E (TTM)
-2.1396
1D
5D
1M
3M
1Y
5Y
1D
Lake Street Remains a Buy on Lantern Pharma (LTRN)
TipRanks · 3d ago
Lantern Pharma Reports Positive Phase 1a Data For LP-184 In Advanced Solid Tumors
NASDAQ · 4d ago
Lantern Pharma announces LP-184 clinical trial met all primary endpoints
TipRanks · 4d ago
LANTERN PHARMA INC: CLINICAL TRIAL MET ALL PRIMARY ENDPOINTS FOR SAFETY, TOLERABILITY, AND ESTABLISHED A CLEAR RECOMMENDED PHASE 2 DOSE
Reuters · 4d ago
Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors
Reuters · 4d ago
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
Barchart · 4d ago
Weekly Report: what happened at LTRN last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at LTRN last week (1117-1121)?
Weekly Report · 11/24 09:17
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.